{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:04:34Z","timestamp":1778508274276,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.bbrc.2006.10.039","type":"journal-article","created":{"date-parts":[[2006,10,24]],"date-time":"2006-10-24T17:57:34Z","timestamp":1161712654000},"page":"273-280","source":"Crossref","is-referenced-by-count":50,"title":["hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656"],"prefix":"10.1016","volume":"351","author":[{"given":"James T.","family":"Milnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry J.","family":"Witchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne L.","family":"Leaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J.","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules C.","family":"Hancox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2006.10.039_bib1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1046\/j.1440-1681.2000.03337.x","article-title":"Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current","volume":"27","author":"Witchel","year":"2000","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib2","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1053\/euhj.2000.2249","article-title":"The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology","volume":"21","author":"Haverkamp","year":"2000","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bbrc.2006.10.039_bib3","first-page":"667","article-title":"Molecular determinants of high-affinity drug binding to HERG channels","volume":"6","author":"Mitcheson","year":"2003","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.bbrc.2006.10.039_bib4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","article-title":"QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients","volume":"355","author":"Reilly","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2006.10.039_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.180.6.515","article-title":"Thioridazine and sudden unexplained death in psychiatric in-patients","volume":"180","author":"Reilly","year":"2002","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bbrc.2006.10.039_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.198.1.134","article-title":"The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogram","volume":"198","author":"Huston","year":"1966","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2006.10.039_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-200302000-00010","article-title":"Psychotropic drugs, cardiac arrhythmia, and sudden death","volume":"23","author":"Witchel","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0009-9236(96)90150-2","article-title":"Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans","volume":"60","author":"Hartigan-Go","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2006.10.039_bib9","first-page":"546","article-title":"Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities","volume":"89","author":"Kelly","year":"1963","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.bbrc.2006.10.039_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-0447.1991.tb01421.x","article-title":"A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland","volume":"84","author":"Mehtonen","year":"1991","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbrc.2006.10.039_bib11","unstructured":"U.S FDA\u2014Mellaril (thioridazine-HCl) Drug Warning. <http:\/\/www.fda.gov\/medwatch\/safety\/2000\/mellar.htm\/>, 2000."},{"key":"10.1016\/j.bbrc.2006.10.039_bib12","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0022-3565(24)38082-6","article-title":"Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current","volume":"288","author":"Drolet","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2006.10.039_bib13","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(05)73083-X","article-title":"The heart of psychotropic drug therapy","volume":"355","author":"Tie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2006.10.039_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","article-title":"Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern","volume":"50","author":"Kirsch","year":"2004","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.bbrc.2006.10.039_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-2999(02)02074-5","article-title":"A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs","volume":"450","author":"Kongsamut","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1081\/DCT-200064482","article-title":"The phenothiazine drugs inhibit hERG potassium channels","volume":"28","author":"Kim","year":"2005","journal-title":"Drug Chem. Toxicol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1124\/jpet.105.093393","article-title":"Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and non-torsadogenic drugs","volume":"316","author":"Katchman","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2006.10.039_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1254\/jphs.FPE0040101","article-title":"Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels","volume":"95","author":"Chiu","year":"2004","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2006.10.039_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1124\/jpet.301.2.427","article-title":"Three-dimensional quantitative structure\u2013activity relationship for inhibition of human ether-a-go-go-related gene potassium channel","volume":"301","author":"Ekins","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2006.10.039_bib20","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1073\/pnas.210244497","article-title":"A structural basis for drug-induced long QT syndrome","volume":"97","author":"Mitcheson","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2006.10.039_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","article-title":"Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature","volume":"74","author":"Zhou","year":"1998","journal-title":"Biophys. J."},{"key":"10.1016\/j.bbrc.2006.10.039_bib22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.bjp.0705335","article-title":"Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652","volume":"139","author":"Milnes","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.yjmcc.2005.09.017","article-title":"Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel","volume":"40","author":"Ridley","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbrc.2005.06.112","article-title":"The N588K-HERG K+ channel mutation in the \u2018short QT syndrome\u2019: mechanism of gain-in-function determined at 37\u00b0C","volume":"334","author":"McPate","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2006.10.039_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.vascn.2005.04.008","article-title":"Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature","volume":"52","author":"Yao","year":"2005","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.bbrc.2006.10.039_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjp.0705283","article-title":"The antipsychotic drug chlorpromazine inhibits HERG potassium channels","volume":"139","author":"Thomas","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib27","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/00005344-200405000-00014","article-title":"Block of HERG human K+ channel and IKr of guinea pig cardiomyocytes by chlorpromazine","volume":"43","author":"Lee","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yjmcc.2003.10.017","article-title":"Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel","volume":"36","author":"Su","year":"2004","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bcp.2005.10.047","article-title":"Block of hERG channel by ziprasidone: biophysical properties and molecular determinants","volume":"71","author":"Su","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib30","first-page":"949","article-title":"High affinity open channel block by dofetilide of HERG expressed in a human cell line","volume":"49","author":"Snyders","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib31","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.94.10.2572","article-title":"Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide","volume":"94","author":"Kiehn","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.bbrc.2006.10.039_bib32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3565(24)37654-2","article-title":"The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG","volume":"286","author":"Rampe","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2006.10.039_bib33","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/sj.bjp.0700989","article-title":"The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes","volume":"120","author":"Suessbrich","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tips.2005.01.003","article-title":"Predicting drug-hERG channel interactions that cause acquired long QT syndrome","volume":"26","author":"Sanguinetti","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2006.10.039_bib35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1211\/0022357001773977","article-title":"Membrane permeation by multidrug-resistance-modulators and non-modulators: effects of hydrophobicity and electric charge","volume":"52","author":"Castaing","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bbrc.2006.10.039_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bbrc.2006.10.039_bib37","unstructured":"Psychopharmacological Drugs Advisory Committee, Briefing document for Zeldox capsules (ziprasidone-HCl), submitted Pfizer Inc. to U.S FDA. <http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3619b1b.pdf\/>, 2000."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X06022777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X06022777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T17:21:55Z","timestamp":1736616115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X06022777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0006291X06022777"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2006.10.039","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}